The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
It is one of 42 drug-making factories in India that the FDA has banned in recent years
Dinesh Thakur is famous for exposing Ranbaxy safety problems
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
India rejects patent on Pfizer's arthritis drug
Cipla has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients
Few drugs in the market are not approved by the authorities and can be life-threatening.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Dr Reddy's will buy some established brands of Belgian drugmaker UCB.
Sun Pharma open to large acquisitions post Ranbaxy.
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
The new drugs to come under price control include commonly-used antibiotics and painkillers
Shares in ITC Ltd , India's largest cigarette maker, closed 5.2 per cent lower in a broader Mumbai market that fell 0.8 percent.
Some Indian generic drugmakers are, however, uncertain about the pace of approvals in the near future.
India had the third-largest number of people living with HIV in the world at the end of 2013 and accounts for about four out of 10 people living with HIV in the Asian region.
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances